Loading clinical trials...

Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia | Clinical Trials | Clareo Health

COMPLETEDPHASE4

Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia

A Placebo-Controlled Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia

NCT00080327•Otsuka Pharmaceutical Development & Commercialization, Inc.

View on ClinicalTrials.gov

Summary

A study to evaluate three doses of aripiprazole versus placebo in patients with an acute episode of schizophrenia

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Men and women, ages 18 and older, with a worsening of schizophrenia symptoms over the past three months

Locations (1)

Bristol-Meyers Squibb Call Center

Wallingford, Connecticut, United States

Key Dates

Start Date

November 1, 2003

Primary Completion Date

September 1, 2004

Completion Date

September 1, 2004

Last Updated

November 11, 2013

Enrollment

370

Estimated participants

Conditions

Schizophrenia

Interventions

Aripiprazole

DRUG

Aripiprazole

DRUG

Aripiprazole

DRUG

Placebo

DRUG

Feasibility, Acceptability, and Preliminary Efficacy of Yoga-based Group Intervention for Outpatients With Schizophrenia Spectrum Disorders

NCT07455929

Psychotic DisordersSchizophrenia Spectrum Disorders

View study

RECRUITING

Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services

NCT06740383

Schizophrenia Spectrum and Other Psychotic DisordersSchizophrenia+5 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 11, 2013Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia

Inclusion Criteria

Feasibility, Acceptability, and Preliminary Efficacy of Yoga-based Group Intervention for Outpatients With Schizophrenia Spectrum Disorders

Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services

A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia

Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Disorders

Develop a Novel Occupational Training Program for Schizophrenia Patients Based on Virtual Reality Techniques

Brain Stimulation to the Hippocampus in Schizophrenia